focus -WSS

focus

author：comprehensive 2025-09-02 08:14:09 - browse：51496

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Court strikes down limits on filming of police in Arizona

focus

WSS

With measles on the rise, a personal story of a devastating disease

Arc Institute generative AI designs new CRISPR systems

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

7 of the most gruesome medical devices in history

Wearables generate powerful data but its not useful to doctors, yet

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

At least 13 dead in Texas as scorching temps continue

Why an extreme heat and wildfire smoke combination can be so dangerous

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Activists slam private health insurers over coverage restrictions

Data integrity in scientific journals requires "effort" by publishers, institutions

Drug repurposing or repositioning? The language matters

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Walensky prepares to leave CDC — and Congress — behind

FDA official pushes for dedicated emerging pathogens team

explore

FDA official pushes for dedicated emerging pathogens team

As Taiwan prepares for anti

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Venture capitalist Bob Kocher on the state of digital health

Court strikes down limits on filming of police in Arizona

focus

focus

focus

Wikipedia